Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective

Peng Yuan, Binghe Xu National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of ChinaCorrespondence: Binghe XuNational Cancer Center, National Clinical Re...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yuan P, Xu B
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	eribulin mesylate breast cancer china Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/93ca463d3c6d472ea7ed8d651f94b2a4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:93ca463d3c6d472ea7ed8d651f94b2a4
record_format	dspace
spelling	oai:doaj.org-article:93ca463d3c6d472ea7ed8d651f94b2a42021-12-02T16:23:31ZClinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective1179-1314https://doaj.org/article/93ca463d3c6d472ea7ed8d651f94b2a42021-02-01T00:00:00Zhttps://www.dovepress.com/clinical-utility-of-eribulin-mesylate-in-the-treatment-of-breast-cance-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Peng Yuan, Binghe Xu National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of ChinaCorrespondence: Binghe XuNational Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of ChinaTel +86 1087788826Email xubinghebm@163.comAbstract: Eribulin mesylate, a synthetic derivative of the anti-mitotic agent halichondrin B, has a unique tubulin-based mechanism of action that is distinct from other anti-microtubule agents including taxanes and vinca alkaloids. Consistent with this unique activity, eribulin has shown clinical efficacy in patients with metastatic breast cancer (MBC) that progressed following prior taxane and anthracycline therapy. The evidence presented in this review indicates that eribulin represents a treatment option for patients with HER2-negative metastatic breast cancer. Improved survival outcomes and better tolerability compared with vinorelbine supported the first approval of eribulin in China in 2019; eribulin was approved for women with locally advanced/metastatic HER2-negative breast cancer after treatment failure with at least two chemotherapy regimens, including an anthracycline and a taxane. Eribulin has also shown promising efficacy in patients with HER2-positive advanced breast cancer when used in combination with trastuzumab or pertuzumab, and subgroup analyses from the Phase III clinical trials support the continued evaluation of eribulin in patients with triple-negative disease. The unique non-mitotic effects of eribulin, including vascular remodeling, coupled with its clinical efficacy and safety profile, may permit the broader use of this agent in patients with MBC.Keywords: eribulin mesylate, breast cancer, ChinaYuan PXu BDove Medical Pressarticleeribulin mesylatebreast cancerchinaNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 13, Pp 135-150 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	eribulin mesylate breast cancer china Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	eribulin mesylate breast cancer china Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Yuan P Xu B Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
description	Peng Yuan, Binghe Xu National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of ChinaCorrespondence: Binghe XuNational Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of ChinaTel +86 1087788826Email xubinghebm@163.comAbstract: Eribulin mesylate, a synthetic derivative of the anti-mitotic agent halichondrin B, has a unique tubulin-based mechanism of action that is distinct from other anti-microtubule agents including taxanes and vinca alkaloids. Consistent with this unique activity, eribulin has shown clinical efficacy in patients with metastatic breast cancer (MBC) that progressed following prior taxane and anthracycline therapy. The evidence presented in this review indicates that eribulin represents a treatment option for patients with HER2-negative metastatic breast cancer. Improved survival outcomes and better tolerability compared with vinorelbine supported the first approval of eribulin in China in 2019; eribulin was approved for women with locally advanced/metastatic HER2-negative breast cancer after treatment failure with at least two chemotherapy regimens, including an anthracycline and a taxane. Eribulin has also shown promising efficacy in patients with HER2-positive advanced breast cancer when used in combination with trastuzumab or pertuzumab, and subgroup analyses from the Phase III clinical trials support the continued evaluation of eribulin in patients with triple-negative disease. The unique non-mitotic effects of eribulin, including vascular remodeling, coupled with its clinical efficacy and safety profile, may permit the broader use of this agent in patients with MBC.Keywords: eribulin mesylate, breast cancer, China
format	article
author	Yuan P Xu B
author_facet	Yuan P Xu B
author_sort	Yuan P
title	Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
title_short	Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
title_full	Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
title_fullStr	Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
title_full_unstemmed	Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
title_sort	clinical utility of eribulin mesylate in the treatment of breast cancer: a chinese perspective
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/93ca463d3c6d472ea7ed8d651f94b2a4
work_keys_str_mv	AT yuanp clinicalutilityoferibulinmesylateinthetreatmentofbreastcancerachineseperspective AT xub clinicalutilityoferibulinmesylateinthetreatmentofbreastcancerachineseperspective
_version_	1718384122366263296

Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective

Ejemplares similares